Drug intelligence / Profile preview

L-pampo

Development stage: Preclinical
Lead developer: CHA Vaccine Institute
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

L-pampo is a vaccine adjuvant composed of a combination of Toll-like receptor 1/2 (TLR1/2) and Toll-like receptor 3 (TLR3) agonists. It is designed to enhance the immune response to vaccine antigens by activating innate immunity, thereby promoting robust and protective adaptive immunity. This adjuvant has been investigated in the context of subunit vaccines, particularly for infectious diseases like COVID-19, where it aims to induce strong humoral and cellular immune responses.

Other names: CTB3+/A2+ vaccineTLR1/2 and TLR3 agonist combination

Targets

TLR1TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on L-pampo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-pampo.

Explore the full profile